Anxiety cholecystokinin

Newel experimental approaches to anxiety therapy include ligands interacting with the ligand-gated ion channels that are selectively activated by nicotine, C qH 4N2 (87), the well-known active ingredient of cigarettes which has anxiolytic actions (42). Cholecystokinin B receptor ligands, specifically the dipeptoid, CI-988 [130404-91 -0] 02 1142 40 (88) have demonstrated anxiolytic activity ia preclinical models (43). [Pg.542]

Cholecystokinin (CCK) is produced in the intestine and the brain. It appears to be an important mediator of anxiety. It also stimulates vasopressin secretion and slows gastric emptying. In addition, it is an important humoral satiety signal (appetite control). Various antagonists have been developed and are currently being investigated with regard to their therapeutic potential. [Pg.356]

Several neuropeptides are under current investigation for their role in anxiety disorders. Important neuropeptides include neuropeptide Y (NPY), substance P, and cholecystokinin. NPY appears to have a role in reducing the effect of stress hormones and inhibiting activity of the LC. Both mechanisms may contribute to the anxiolytic properties seen experimentally. Substance P may have anxiolytic and antidepressant properties. This may be due in part to its effects on corticotropin-releasing hormone.21... [Pg.608]

There has been a plethora of linkage and association studies attempting to identify genes for anxiety disorders. The neurotransmitter systems that have been implicated in anxiety disorders include adenosine, adrenaline, noradrenaline, dopamine, serotonin, cholecystokinin, and y-aminobutyric acid (GABA). In... [Pg.166]

Mezey E, Reisine TD, Skirboll L, Beinfeld M, Kiss JZ (1985) Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus coexistence with corticotropinreleasing hormone. Ann NY Acad Sci 448 152-156 Miller CC, Holmes PV, Edwards GL (2002) Area postrema lesions elevate NPY levels and decrease anxiety-related behavior in rats. Physiol Behav 77 135-140 Miyasaka K, Kobayashi S, Ohta M, Kanai S, Yoshida Y, Nagata A, Matsui T, Noda T, Takiguchi S, Takata Y, Kawanami T, Funakoshi A (2002) Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci Lett 335 115-118... [Pg.364]

Dorow R, Horowski R, Paschelke G, Amin M (1983) Severe anxiety induced by EG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 2 98-99 Erankland PW, Josselyn SA, Bradwejn J, Vaccarino PJ, Yeomans JS (1997) Activation of amygdala cholecystokinin B receptors potentiates the acoustic startle response in the rat. J Neurosci 17 1838-1847... [Pg.464]

Harro J, Vasar E, Bradwejn J (1993) Cholecystokinin in animal and human research of anxiety. Trends Pharmacol Sci 14 244-249... [Pg.464]

Lesch KP, Wiesmann M, Hoh A (1992) 5-HTlA receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl) 106 111-117 Levin AP, Doran AR, Liebowitz MR, Fyer AJ, Klein DF, Paul SM (1987) Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21 23-32 Lines C, Challenor J, Traub M (1995) Cholecystokinin and anxiety in normal volunteers—an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype-b-antagonist L-365,260. Br J Clin Pharmacol 39 235-242 Low K, Crestani F, Keist R, Benke D, Brunig I (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290 131-134 Lucki I (1996) Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry 57(Suppl 6) 5-10... [Pg.465]

Miyasaka K, Kobayashi S, Ohta M, Kanai S, Yoshida Y, Nagata A, Matsui T, Noda T, Takuguchi S, Takata Y, Kawanami T, Funakoshi A (2002) Anxiety-related behaviors in cholecystokinin-A,B, and AB receptor gene knockout mice in the plus-maze. Neurosci Lett 335 115-118... [Pg.466]

To date, evidence suggests that cholecystokinin-B activation may trigger a cascade of neurochemical events culminating in both the psychic and the somatic features of anxiety. In summary, these data continue to suggest an interesting opportunity to qualitatively broaden the clinician s armamentarium against one or more of the anxiety disorders. [Pg.406]

THERE AN ALTERED FUNCTION OF THE CHOLECYSTOKININ SYSTEM IN ANXIETY STATES IN HUMANS ... [Pg.422]

Abelson JL, Cameron OG Adrenergic dysfunction in anxiety disorders, in Adrenergic Dysfunction and Psychobiology. Edited by Cameron OG. Washington, DC, American Psychiatric Press, 1995, pp 403-446 Abelson JL, Nesse RM Cholecystokinin-4 and panic (comment). Arch Gen Psychiatry 47 395, 1990... [Pg.581]

Bradwejn J, Koszycki D The cholecystokinin hypothesis of anxiety and panic disorders. Ann N Y Acad Sci 713 273-282, 1994a... [Pg.602]

Bradwejn J, Koszycki D, Payeur R Study of the replication of action of cholecystokinin in panic disorders. Am J Psychiatry 149 962-964, 1992c Bradwejn J, Koszycki D, Couetoux-Dutertre AC, et al L-365,260, a CCK-B receptor antagonist, blocks CCK-4 panic (oral presentation). Presented at the annual meeting of the Anxiety Disorders Association of America (NR 235), Charleston, SC, March 20, 1993... [Pg.603]

Hill DR, Woodruff GN, Hughes J Cholecystokinin receptor subtypes and their potential involvement in anxiety, in Abstracts of Panels and Posters of the 32nd Annual Meeting of American College of Neuropsychopharmacology, Honolulu, HI, American College of Neuropsychopharmacology, 1993, p 58... [Pg.658]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...